Natures Pharmacy Recalls Vit A Ophthalmic Drops for Sterility Concerns
Natures Pharmacy & Compounding Center is recalling Vit A (olive oil) 0.1% ophthalmic drops due to quality control issues affecting sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of sterility assurance in ophthalmic products, which poses a significant risk of serious injury or infection.
Plain-English summary
Natures Pharmacy & Compounding Center is recalling all lots of Vit A (olive oil) 0.1% ophthalmic drops that are not expired. The recall was initiated due to concerns regarding quality control procedures that present a potential risk to sterility assurance.
These concerns were identified during a recent FDA inspection of the pharmacy. The recall covers all lots of sterile products compounded by the facility that are within their expiration dates.
Consumers who have this product should stop using it and contact their healthcare provider or the pharmacy for further instructions.
The recalled product
- Product
- Vit A (olive oil) 0.1% opth.
- Manufacturer
- Natures Pharmacy & Compounding Center
- Category
- Drug — Ophthalmic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lot numbers within expiry.
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 48 recalled by Natures Pharmacy & Compounding Center under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 48 products in this recall →Related recalls
Same manufacturer · Natures Pharmacy & Compounding Center
See all →- SevereNatures Pharmacy Recalls Triamcinolone Acetonide Due to Sterility Concerns
FDA (Drugs) · 2014-03-12
- SevereSodium Bicarbonate Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12
- SevereFDA Recalls Estradiol and Testosterone Compounds for Sterility Concerns
FDA (Drugs) · 2014-03-12
- SevereNatures Pharmacy Recalls Glutathione Inhalation Due to Sterility Concerns
FDA (Drugs) · 2014-03-12
- SevereNatures Pharmacy Recalls Voriconazole Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-03-12
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- SevereHealth Innovations Pharmacy Recalls Voriconazole Eye Drops for Sterility Concerns
FDA (Drugs) · 2015-05-20
- HighAcetylcysteine eye drops recalled for sterility assurance defect
FDA (Drugs) · 2022-11-09
- HighGlycerin Ophthalmic Drops Recalled Due to Sterility Manufacturing Concerns
FDA (Drugs) · 2022-11-09
- SevereCyclosporine 1% Ophthalmic Drops Recalled for Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Laser Ophthalmic Drops
FDA (Drugs) · 2013-07-10
- SevereFDA Recalls Atropine Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2019-04-24